Serfaty D, Vree M L
Hospital Saint-Louis, Paris, France.
Eur J Contracept Reprod Health Care. 1998 Dec;3(4):179-89. doi: 10.3109/13625189809167251.
To compare the cycle control and tolerability of two oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.
A randomized, multicenter study was conducted in which 1016 healthy adult women received the desogestrel (n = 509) or the gestodene (n = 507) preparation for six treatment cycles.
No significant differences in bleeding patterns were detected between the two treatments. The incidence and duration of irregular bleeding decreased markedly, and to a similar extent, during each treatment. The occurrence of irregular bleeding per cycle decreased from 24.6 to 9.4% in the desogestrel group and from 19.7 to 8.6% in the gestodene group. Its duration fell from 1.1 to 0.2 days and from 0.9 to 0.3 days, respectively. There was a consistently low incidence of amenorrhea (1.0-2.8%). There were no significant differences between treatments for the incidence, intensity or emergence of dysmenorrhea. During both treatments, the incidence of premenstrual syndrome and complaints such as breast tenderness, nausea and headache dropped markedly.
Ultra low-dose oral contraceptives containing desogestrel or gestodene offer equivalent, good cycle control and improvements in dysmenorrhea and premenstrual syndrome and have similar, excellent tolerability profiles.
比较两种含20微克炔雌醇及150微克去氧孕烯或75微克孕二烯酮的口服避孕药的周期控制情况和耐受性。
开展一项随机、多中心研究，1016名健康成年女性接受去氧孕烯制剂（n = 509）或孕二烯酮制剂（n = 507）治疗六个周期。
两种治疗方法在出血模式上未检测到显著差异。在每个治疗周期中，不规则出血的发生率和持续时间均显著下降，且下降程度相似。去氧孕烯组每个周期不规则出血的发生率从24.6%降至9.4%，孕二烯酮组从19.7%降至8.6%。其持续时间分别从1.1天降至0.2天和从0.9天降至0.3天。闭经发生率始终较低（1.0 - 2.8%）。痛经的发生率、严重程度或出现情况在两种治疗方法之间无显著差异。在两种治疗过程中，经前综合征以及乳房胀痛、恶心和头痛等不适症状的发生率均显著下降。
含去氧孕烯或孕二烯酮的超低剂量口服避孕药在周期控制方面效果相当，对痛经和经前综合征有改善作用，且耐受性相似，均表现出色。
